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A prospective study to investigate three fully
oral regimens of 6 or 8 months’ duration, with
varying frequencies of attendance and different
rhythms of drug intake is reported.
Patients were randomly allocated, irrespective
of their previous chemotherapy, to one of the
following regimens :
1. 2EHRZ7 (ow)/6EH7 (tw) : Fully self-
administered daily regimen of 8 months’
duration. Ethambutol 600 mg, Isoniazid 300 mg,
Rifampicin 4.50 mg and Pyrazinamide 1.5 g daily
for the first 2 months, followed by Ethambutol
600 mg and Isoniazid 300 mg, daily for the next 6
months. The patients were required to attend the
clinic once a week during the first 2 months and
twice a month during the next 6 months for drug
collection.
2. 2EHRZ2/4EHR2 (tw) or 2EHRZ2/
4EHR2 (ow): Twice-weekly regimen of 6
months’ duration; Ethambutol 1200 mg, Isoniazid
600 mg, Rifampicin 450 mg and Pyrazinamide 2.0
g during the first two months and Ethambutol,
Isoniazid and Rifampicin in the same dosages
during the next 4 months. Half the patients, by
random allocation, received fully supervised
chemotherapy necessitatingtwice weekly
attendance at the Clinic throughout while the
other half attend only once a week, when one
dose is given under supervision and the other  
dose is supplied for self-administration.
3. 2HRZ2/4HR2 (tw) or 2HRZ2/2HR2 
(ow) : similar to regimen 2, but without  
Ethambutol.
The interim findings of the study in 1044 g
patients including relapse upto 24 months were
presented.
